ReviewMolecules (Basel, Switzerland)2026
Recent Advances in Organocatalytic Kinetic Resolution for the Synthesis of Axially Chiral Compounds.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Axially chiral compounds, indispensable in asymmetric catalysis, drug discovery, and materials science, have witnessed transformative advancements in synthesis through organocatalytic kinetic resolution (OKR) over the past decade. This review systematically dissects the latest achievements (2010-2025) in OKR, focusing on catalyst design, mechanistic insights, substrate diversification, and synthetic applications across C-C biaryl, C-N heterobiaryl, and olefinic axially chiral frameworks. By harnessing non-covalent interactions, OKR has emerged as a powerful strategy to overcome the challenges of low rotational barriers and limited stereocontrol, offering sustainable and enantioselective access to privileged chiral scaffolds. Furthermore, the current challenges and future prospects in this rapidly evolving field are assessed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.